retatrutide clinical trials phase 3 Results: TRIUMPH-1 Data Explained Retatrutide Achieves Up to 30.3%

To be included in the Bridge eligibility analysis, an individual was required to have coverage for Parts A, B, and D for all months of 2023, not have switched between traditional Medicare and Medicare Advantage during the year, and remain living for the entire year

Always prioritise evidence-based treatments recommended by your healthcare team

Retracted: Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor [PMID: 20302919] Laboratory literature summary: Retracted: Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy

Table 1 Human clinical studies evaluating gut microbiota changes and microbial features associated with GLP-1 receptor agonist therapy